High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone

被引：0
|
作者：
Farag, Sarah
Bacher, Ulrike
Legros, Myriam
Betticher, Daniel
Luthi, Jean-Marc
Egger, Thomas
Zander, Thilo
Jeker, Barbara
Pabst, Thomas
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141545
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone
    Ferini, G. A.
    Arbelbide, J. A.
    Basquiera, A. L.
    Nucifora, E.
    Schutz, N.
    Otero, V.
    Fantl, D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S461 - S462
  • [32] Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
    Dumontet, C.
    Landi, S.
    Reiman, T.
    Perry, T.
    Plesa, A.
    Bellini, I.
    Barale, R.
    Pilarski, L. M.
    Troncy, J.
    Tavtigian, S.
    Gemignani, F.
    BONE MARROW TRANSPLANTATION, 2010, 45 (08) : 1316 - 1324
  • [33] High remission rate with high dose melphalan and etoposide (VP-16) and autologous stem cell support in newly diagnosed multiple myeloma (MM) patients.
    Hardan, I
    Raz, H
    Avigdor, A
    Attias, D
    Kneller, R
    Berkowicz, M
    Bracha, D
    Sareli, R
    Raanani, P
    Levy, I
    Ben-Bassat, I
    BONE MARROW TRANSPLANTATION, 1999, 23 : S135 - S135
  • [34] High-dose therapy autotransplantation/intensification in multiple myeloma: pretransplant predictors of complete remission
    Gine, E
    Nadal, E
    Blade, J
    Esteve, J
    Aviles, FF
    Martinez, C
    Rovira, M
    Ispizua, AU
    Marin, P
    Nomdedeu, B
    Carreras, E
    Montserrat, E
    BONE MARROW TRANSPLANTATION, 2003, 31 : S84 - S85
  • [35] Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Aleman, Ana
    Lei, X.
    Weber, Donna
    Carrasco, Antonio
    Champlin, Richard E.
    Giralt, Sergio A.
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1360 - 1364
  • [36] Melphalan and prednisone (MP) followed by interferon plus dexamethasone maintenance therapy improves remission duration of myeloma patients.
    Boccadoro, M
    Agentino, C
    Avvisati, G
    Baldini, L
    Bidoli, P
    Capaldi, A
    Callea, V
    Cimino, R
    Comotti, B
    DeRenzo, A
    Dominietto, A
    Falini, B
    Frieri, R
    Gallone, G
    Grasso, M
    Iannitto, E
    Lauta, VM
    Liberati, M
    Marceno, R
    Marmont, F
    Molica, S
    Musto, P
    Palumbo, A
    Pulsoni, A
    Rus, C
    Tribalto, M
    Pileri, A
    Mandelli, F
    BLOOD, 1997, 90 (10) : 1586 - 1586
  • [37] Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
    Hagen, Patrick
    Norton, Joseph
    Tsai, Stephanie
    Campo, Loredana
    Lee, Mary
    Gomez, Kayeromi
    Stiff, Patrick
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1422 - 1428
  • [38] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    Singhal, S
    Powles, R
    Sirohi, B
    Treleaven, J
    Kulkarni, S
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2002, 30 (10) : 673 - 679
  • [39] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    S Singhal
    R Powles
    B Sirohi
    J Treleaven
    S Kulkarni
    J Mehta
    Bone Marrow Transplantation, 2002, 30 : 673 - 679
  • [40] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    Singhal, S
    Powles, R
    Sirohi, B
    Kulkarni, S
    Treleaven, J
    Goyal, S
    Sankpal, S
    Rao, S
    Saso, R
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2002, 29 : S103 - S103
12345